Physician profile
Sandra Ojeda
NPI 1215728902
$930.83
in general payments reported to CMS, 2019-2025
13 companies · $931 in 2025
The $931 reported for 2025 was more than what 84% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $931.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $931.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $930.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $374.92 | 2025 | |
| Ucb, INC. | $147.16 | 2025 | Bimzelx |
| Astrazeneca Pharmaceuticals LP | $86.73 | 2025 | Saphnelo |
| Pfizer INC. | $65.79 | 2025 | |
| Mallinckrodt Hospital Products INC. | $51.08 | 2025 | Acthar |
| Janssen Biotech, INC. | $45.50 | 2025 | Tremfya |
| Octapharma USA, INC. | $34.67 | 2025 | Octagam Immune Globulin (Human) |
| Alexion Pharmaceuticals, INC. | $30.66 | 2025 | Strensiq |
| Biocon Biologics INC | $27.21 | 2025 | Yesintek |
| Glaxosmithkline, LLC. | $20.70 | 2025 | Arexvy, Trelegy Ellipta |
| Amgen INC. | $16.39 | 2025 | Evenity |
| E.R. Squibb & Sons, L.L.C. | $16.37 | 2025 | Orencia |
| Novartis Pharmaceuticals Corporation | $13.65 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Ojeda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.